Boulder, CO – According to filings with the U.S. Securities and Exchange Commission, OnKure is raising $5,236,935.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Anthony Piscopio played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About OnKure

OnKure is engaged in the discovery and development of epigenetic therapies for the treatment of cancer that include selective inhibitors of histone deacetylases (HDACs). In pre-clinical models of both hematological and solid tumor cancers, our lead candidate, OKI-179, significantly and safely reduces the growth rate of tumors when dosed by itself or in combination with other targeted therapies.

To learn more about OnKure, visit http://onkuretherapeutics.com/

Contact:
Anthony Piscopio, Chief Executive Officer
720-307-2892
https://www.linkedin.com/in/tony-piscopio-93a2338/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved